You are here

Manufacturer of Symlin Submits Complete Response to FDA

SAN DIEGO, Sept. 20 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. today announced the submission of a complete response to the U.S. Food and Drug Administration's second approvable letter for SYMLIN® (pramlintide acetate). Resubmission of a complete response after receipt of an approvable letter is intended to answer all of the questions that need to be addressed prior to approval. The FDA is expected to respond to this new submission within six months.

"Based on numerous discussions with the FDA, we believe that data generated since our last SYMLIN® submission in June 2003 and additional analyses of earlier studies, including the pivotal studies, answer the questions raised in the second approvable letter," said Ginger L. Graham, President and CEO of Amylin Pharmaceuticals, Inc.

Recent Headlines

Disrupting Gut Microbiome Could Be Key
Drug Boosts Levels of Natural Endocannabinoids
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment
Vitamin E Found in Samples Around the Country
Study Links Them to Premature Death
Nag With Texting and a ‘Winners Circle’
How Serotonin and Fluoxetine Affect Microbiota Residing in the Gut